261 related articles for article (PubMed ID: 16686692)
1. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
[TBL] [Abstract][Full Text] [Related]
2. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
3. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
6. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
8. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
[TBL] [Abstract][Full Text] [Related]
10. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Dong Z; Wolfer DP; Lipp HP; Büeler H
Mol Ther; 2005 Jan; 11(1):80-8. PubMed ID: 15585408
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
[TBL] [Abstract][Full Text] [Related]
12. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.
Mochizuki H; Hayakawa H; Migita M; Shibata M; Tanaka R; Suzuki A; Shimo-Nakanishi Y; Urabe T; Yamada M; Tamayose K; Shimada T; Miura M; Mizuno Y
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10918-23. PubMed ID: 11535810
[TBL] [Abstract][Full Text] [Related]
13. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Lau YS; Novikova L; Roels C
Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837
[TBL] [Abstract][Full Text] [Related]
14. In vivo modulation of the Parkinsonian phenotype by Nrf2.
Burton NC; Kensler TW; Guilarte TR
Neurotoxicology; 2006 Dec; 27(6):1094-100. PubMed ID: 16959318
[TBL] [Abstract][Full Text] [Related]
15. Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice.
Sakai R; Irie Y; Murata T; Ishige A; Anjiki N; Watanabe K
Phytother Res; 2007 Sep; 21(9):868-73. PubMed ID: 17486689
[TBL] [Abstract][Full Text] [Related]
16. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity.
Choi JY; Jang EH; Park CS; Kang JH
Free Radic Biol Med; 2005 Mar; 38(6):806-16. PubMed ID: 15721991
[TBL] [Abstract][Full Text] [Related]
17. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
18. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
19. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
[TBL] [Abstract][Full Text] [Related]
20. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
Cleren C; Starkov AA; Calingasan NY; Lorenzo BJ; Chen J; Beal MF
Neurobiol Dis; 2005 Dec; 20(3):701-8. PubMed ID: 16126396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
